Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 2:04 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1369–1392 of 1,622 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Retinal Disorder Clear all

Conditions: Diabetic Macular Edema
Interventions: Experimental: Group 1 - 50mg RZ402, Experimental: Group 2 - 200mg RZ402, Experimental: Group 3 - 400mg RZ402, Placebo: Group 4 - Placebo; Drug · Other
Lead sponsor: Rezolute; Other
Eligibility: 18 Years to 75 Years
Enrollment: 94 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 32
States / cities: Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 29 more

Conditions: Pain, Retinopathy of Prematurity
Interventions: Proparacaine Hydrochloride Ophthalmic Solution; Drug
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: Not listed
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Glaucoma, Macular Disease, Keratoconus
Interventions: OCT imaging, the FDA Cleared iVue; Device
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 18 Years to 89 Years
Enrollment: 118 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2017
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Retinitis Pigmentosa, Usher Syndrome Type 2
Interventions: RNA antisense oligonucleotide for intravitreal injection; Drug
Lead sponsor: Laboratoires Thea; Industry
Eligibility: 12 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 4
States / cities: Boston, Massachusetts • Ann Arbor, Michigan • Portland, Oregon + 1 more

Conditions: Retinopathy of Prematurity
Interventions: Bevacizumab, Laser; Drug · Procedure
Lead sponsor: Jaeb Center for Health Research; Other
Eligibility: Up to 6 Months
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 32
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Irvine, California + 26 more

Conditions: Cystoid Macular Edema,, Retinal Thickening
Interventions: 2. Xibrom (Bromfenac), 1. Pred Forte; Drug
Lead sponsor: Center For Excellence In Eye Care; Other
Eligibility: 18 Years and older
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Age Related Macular Degeneration
Interventions: Ranibizumab; Drug
Lead sponsor: Vitreous -Retina- Macula Consultants of New York; Other
Eligibility: 50 Years and older
Enrollment: 9 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: New York, New York

Conditions: Age-Related Macular Degeneration
Interventions: E10030, ranibizumab, E10030 sham intravitreal injection; Drug
Lead sponsor: Ophthotech Corporation; Industry
Eligibility: 50 Years and older
Enrollment: 619 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 50
States / cities: Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 44 more

Conditions: Aging, Age-Related Macular Degeneration
Interventions: ZeaVision EyePromise Restore, Multivitamin; Dietary Supplement
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 60 Years to 80 Years
Enrollment: 13 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Retinal Disease, Macular Degeneration, Hereditary Retinal Dystrophy, Optic Nerve Disease, Glaucoma
Interventions: RB (Retrobulbar), ST (Subtenon), IV (Intravenous), IVIT (Intravitreal), IO (Intraocular); Procedure
Lead sponsor: MD Stem Cells; Industry
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2020
U.S. locations: 1
States / cities: Westport, Connecticut

Conditions: Age-Related Macular Degeneration
Interventions: Ranibizumab, Ranibizumab plus Photodynamic therapy; Drug
Lead sponsor: Illinois Retina Associates; Other
Eligibility: 50 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Oak Park, Illinois

Conditions: Fibromyalgia, Musculoskeletal Pain
Interventions: S-Cone Stimulating Chromatic Light, Equal-Energy White Light; Device
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Retinal Vascular Disorder, Macular Degeneration
Interventions: Not listed
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years to 115 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Retinitis Pigmentosa, Retinitis, Retinal Diseases, Eye Diseases, Eye Diseases, Hereditary, Retinal Dystrophies, Retinal Degeneration
Interventions: Gene Therapy product-MCO-010; Biological
Lead sponsor: Nanoscope Therapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 5
States / cities: Beverly Hills, California • Pensacola, Florida • Fargo, North Dakota + 2 more

Conditions: Retinitis Pigmentosa, Visual Impairment, Visual Prosthesis
Interventions: Navigation system mode: Argus Vision, Navigation system mode: Depth Vision, Navigation system mode: Depth Vision with Haptic / Audio, Navigation system mode: Haptic / Audio, Navigation system mode: High Field-of-View Depth Vision, Distance test vision mode: Low Resolution / Low Field-of-View, Distance test vision mode: Low Resolution / High Field-of-View, Distance test vision mode: High Resolution / Low Field-of-View, Distance test vision mode: High Resolution / High Field-of-View; Device
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2024
U.S. locations: 2
States / cities: Baltimore, Maryland • Laurel, Maryland

Conditions: Central Retinal Vein Occlusion
Interventions: fluocinolone acetonide (Retisert Implant, Bausch and Lomb); Device
Lead sponsor: Glenn Jaffe; Other
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2009
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Retinal Neovascularization
Interventions: Not listed
Lead sponsor: Notal Vision Inc.; Industry
Eligibility: 55 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 3
States / cities: Boston, Massachusetts • St Louis, Missouri • Florence, South Carolina

Conditions: Choroiditis, Iridocyclitis, Iritis, Retinal Disease
Interventions: Not listed
Lead sponsor: National Eye Institute (NEI); NIH
Eligibility: 4 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2008
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Geographic Atrophy, Macular Degeneration
Interventions: Avacincaptad Pegol, Sham; Drug
Lead sponsor: IVERIC bio, Inc.; Industry
Eligibility: 50 Years and older
Enrollment: 448 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 96
States / cities: Beverly Hills, California • Campbell, California • Fresno, California + 86 more

Conditions: Geographic Atrophy, Age-Related Macular Degeneration
Interventions: Emixustat HCl Tablet, Placebo Tablet; Drug · Other
Lead sponsor: Kubota Vision Inc.; Industry
Eligibility: 65 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Age-Related Macular Degeneration
Interventions: Active Comparator CT1812, Placebo Comparator; Drug
Lead sponsor: Cognition Therapeutics; Industry
Eligibility: 50 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 19
States / cities: Phoenix, Arizona • Sacramento, California • Walnut Creek, California + 15 more

Conditions: Macular Degeneration
Interventions: Rheopheresis blood filtration; Device
Lead sponsor: OccuLogix; Industry
Eligibility: 0 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 8
States / cities: Beverly Hills, California • Coral Gables, Florida • Fort Myers, Florida + 5 more

Conditions: Cytomegalovirus Retinitis, HIV Infections
Interventions: Foscarnet sodium, Ganciclovir; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 9
States / cities: La Jolla, California • Los Angeles, California • San Francisco, California + 4 more

Conditions: Cytomegalovirus Retinitis, HIV Infections
Interventions: Nelfinavir mesylate; Drug
Lead sponsor: Agouron Pharmaceuticals; Industry
Eligibility: 13 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 8
States / cities: Los Angeles, California • Orange, California • San Diego, California + 5 more

Search by objective public record fields.

Study to Evaluate the Efficacy and Safety of RZ402 in Diabetic Macular Edema (DME)

Proparacaine and Mydriatic Eye Drops

CEI Van Outreach Screening Study

An Open-Label Extension Study to Evaluate Safety & Tolerability of QR-421a in Subjects With Retinitis Pigmentosa

A Randomized Trial of Low-Dose Bevacizumab vs Laser for Type 1 ROP

Bromfenac BID Plus Prednisolone Acetate BID Versus Bromfenac BID Plus Prednisolone QID for the Prevention of Cystoid Macular Edema and Retinal Thickening

A Pilot Study to Evaluate the Role of High-dose Ranibizumab (2.0mg) in the Management of AMD in Patients With Persistent/Recurrent Macular Fluid Less Than 30 Days Following Treatment With Intravitreal Anti-VEGF Therapy (the LAST Study)

A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Lucentis® Compared to Lucentis® Monotherapy

Investigation of Macular Pigment Augmentation on Dark Adaptation

Stem Cell Ophthalmology Treatment Study

Combination Lucentis and Ocular Photodynamic Therapy With Visudyne, With Evaluation-based Retreatment

Light Bulb Stimuli to Reduce Chronic Pain

Ocular Imaging Study Using Advanced OCT

Non-Interventional Long Term Follow-up Study of Participants Previously Enrolled in the RESTORE Study

Environmental Localization Mapping and Guidance for Visual Prosthesis Users

A Study of a Sustained Release Fluocinolone Implant for Treatment of Central Retinal Vein Occlusion

Home OCT Guided Management Study of Subjects Diagnosed With Neovascular-AMD

Evaluation and Treatment of Patients With Inflammatory Eye Diseases

A Phase 3 Safety and Efficacy Study of Intravitreal Administration of Zimura (Complement C5 Inhibitor)

Pharmacokinetic and Pharmacodynamic Study of Emixustat in Subjects With Geographic Atrophy Associated With Dry Age-Related Macular Degeneration

Study to Evaluate the Efficacy and Safety of Oral CT1812 in Participants With Geographic Atrophy (GA) Secondary to Dry Age-Related Macular Degeneration (AMD).

Long-Term Efficacy in AMD of Rheopheresis in North America

CMV Retinitis Retreatment Trial

A Study of Viracept in AIDS Patients With Cytomegalovirus Retinitis